Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sodium Acetate
Therapeutic Area : Nephrology
Study Phase : Approved
Sponsor : Woodward Pharma Services
Deal Size : Not Applicable
Deal Type : Not Applicable
A.forall Announces Launch of a Generic Version of Sodium Acetate Injection 4 mEq/mL
Details : Sodium Acetate-generic Injection is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake.
Brand Name : Sodium Acetate-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 09, 2024
Lead Product(s) : Sodium Acetate
Therapeutic Area : Nephrology
Highest Development Status : Approved
Sponsor : Woodward Pharma Services
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pyridostigmine
Therapeutic Area : Immunology
Study Phase : Approved
Recipient : Acella Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
A.forall Announces Launch of a Generic Version of Pyridostigmine Bromide Syrup
Details : Pyridostigmine Bromide, generic version of Mestinon, is a cholinesterase inhibitor small molecule drug administered orally as a syrup for myasthenia gravis.
Brand Name : Mestinon-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 11, 2023
Lead Product(s) : Pyridostigmine
Therapeutic Area : Immunology
Highest Development Status : Approved
Recipient : Acella Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dexmedetomidine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Dexmedetomidine hydrochloride Injection is indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting.
Brand Name : Precedex-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 09, 2023
Lead Product(s) : Dexmedetomidine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pyridostigmine
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Alter Pharma group
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Abbreviated New Drug Application (ANDA) for a generic version of Mestinon (Pyridostigmine Bromide Syrup) 60 mg/5mL, is indicated for symptomatic treatment of myasthenia gravis.
Brand Name : Pyridostigmine Bromide-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 19, 2022
Lead Product(s) : Pyridostigmine
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Alter Pharma group
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?